106 related articles for article (PubMed ID: 16243564)
41. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
[TBL] [Abstract][Full Text] [Related]
42. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
[TBL] [Abstract][Full Text] [Related]
43. A simian human immunodeficiency virus with a nonfunctional Vpu (deltavpuSHIV(KU-1bMC33)) isolated from a macaque with neuroAIDS has selected for mutations in env and nef that contributed to its pathogenic phenotype.
Singh DK; McCormick C; Pacyniak E; Lawrence K; Dalton SB; Pinson DM; Sun F; Berman NE; Calvert M; Gunderson RS; Wong SW; Stephens EB
Virology; 2001 Mar; 282(1):123-40. PubMed ID: 11259196
[TBL] [Abstract][Full Text] [Related]
44. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
45. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
46. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
47. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
[No Abstract] [Full Text] [Related]
48. Multiple subsets of HIV-specific cytotoxic T lymphocytes in humans and in mice.
Chenciner N; Michel F; Dadaglio G; Langlade-Demoyen P; Hoffenbach A; Leroux A; Garcia-Pons F; Rautmann G; Guy B; Guillon JM
Eur J Immunol; 1989 Sep; 19(9):1537-44. PubMed ID: 2676560
[TBL] [Abstract][Full Text] [Related]
49. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.
Wyatt LS; Earl PL; Liu JY; Smith JM; Montefiori DC; Robinson HL; Moss B
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):645-53. PubMed ID: 15242542
[TBL] [Abstract][Full Text] [Related]
50. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
51. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.
Burgers WA; Shephard E; Monroe JE; Greenhalgh T; Binder A; Hurter E; Van Harmelen JH; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):195-206. PubMed ID: 18240957
[TBL] [Abstract][Full Text] [Related]
52. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
[TBL] [Abstract][Full Text] [Related]
53. Coping with viral diversity in HIV vaccine design: a response to Nickle et al.
Fischer W; Liao HX; Haynes BF; Letvin NL; Korber B
PLoS Comput Biol; 2008 Jan; 4(1):e15; author reply e25. PubMed ID: 18225944
[No Abstract] [Full Text] [Related]
54. Rational vaccine strategies against AIDS: background and rationale.
Ensoli B
Microbes Infect; 2005 Nov; 7(14):1445-52. PubMed ID: 16213183
[TBL] [Abstract][Full Text] [Related]
55. Attenuated nef DNA vaccine construct induces cellular immune response: role in HIV-1 multiprotein vaccine.
Majumder B; Gray B; McBurney S; Schaefer TM; Dentchev T; Mahalingam S; Reinhart TA; Ayyavoo V
Immunol Lett; 2003 Oct; 89(2-3):207-14. PubMed ID: 14556980
[TBL] [Abstract][Full Text] [Related]
56. Progress in AIDS vaccine development.
Johnston MI
Int Arch Allergy Immunol; 1995 Dec; 108(4):313-7. PubMed ID: 7580300
[TBL] [Abstract][Full Text] [Related]
57. Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.
Ferrantelli F; Buttò S; Cafaro A; Wahren B; Ensoli B
Springer Semin Immunopathol; 2006 Nov; 28(3):289-301. PubMed ID: 16983452
[TBL] [Abstract][Full Text] [Related]
58. Nef vaccination against HIV disease.
Montagnier L
Lancet; 1995 Oct; 346(8983):1170. PubMed ID: 7475644
[No Abstract] [Full Text] [Related]
59. Coping with viral diversity in HIV vaccine design.
Nickle DC; Rolland M; Jensen MA; Pond SL; Deng W; Seligman M; Heckerman D; Mullins JI; Jojic N
PLoS Comput Biol; 2007 Apr; 3(4):e75. PubMed ID: 17465674
[TBL] [Abstract][Full Text] [Related]
60. Looking for leads in HIV's battle with immune system.
Cohen J
Science; 1997 May; 276(5316):1196-7. PubMed ID: 9182329
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
